

Yoshito Komatsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214451/publications.pdf>

Version: 2024-02-01

235
papers

4,871
citations

186265

28
h-index

110387

64
g-index

249
all docs

249
docs citations

249
times ranked

5557
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1224-1235.	10.7	1,932
2	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	10.7	234
3	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	30.7	209
4	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1899-1903.	30.7	110
5	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832.	5.3	91
6	Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. <i>Oncologist</i> , 2018, 23, 7-15.	3.7	82
7	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 927-938.	5.3	67
8	Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 566-571.	1.4	67
9	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. <i>Oncologist</i> , 2016, 21, 1483-1491.	3.7	64
10	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 982-986.	6.4	64
11	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	7.0	62
12	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	5.3	60
13	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 198-205.	2.3	57
14	Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1-LBA1.	1.6	52
15	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. <i>European Journal of Cancer</i> , 2018, 91, 86-91.	2.8	48
16	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. <i>European Journal of Cancer</i> , 2020, 129, 97-106.	2.8	48
17	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	7.0	44
18	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4006-4006.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. <i>Gastric Cancer</i> , 2019, 22, 817-827.	5.3	42
20	Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4100-4100.	1.6	40
21	Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. <i>Cancer Science</i> , 2015, 106, 891-895.	3.9	39
22	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	7.0	39
23	Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. <i>European Journal of Cancer</i> , 2019, 121, 29-39.	2.8	38
24	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. <i>Pancreatology</i> , 2018, 18, 647-654.	1.1	35
25	Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.. <i>Journal of Clinical Oncology</i> , 2015, 33, 749-749.	1.6	34
26	Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4009-4009.	1.6	33
27	A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). <i>Oncologist</i> , 2017, 22, 592-600.	3.7	30
28	Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1032-1043.	3.9	30
29	Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. <i>Oncologist</i> , 2019, 24, e450-e457.	3.7	28
30	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). <i>Oncologist</i> , 2020, 25, e1855-e1863.	3.7	28
31	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. <i>Cancer Research</i> , 2021, 81, CT010-CT010.	0.9	28
32	Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. <i>International Journal of Clinical Oncology</i> , 2015, 20, 905-912.	2.2	27
33	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1197-1207.	2.3	27
34	Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27
35	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. <i>Gastric Cancer</i> , 2018, 21, 429-438.	5.3	26
36	capecitabine plus 5-FU/LV versus 5-FU/LV in postoperative gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. <i>Cancer Medicine</i> , 2020, 9, 9396-9408.	2.8	26

#	ARTICLE	IF	CITATIONS
37	The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. <i>Oncologist</i> , 2021, 26, 845-853.	3.7	26
38	Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 473-480.	2.6	25
39	Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSCG0302). <i>Oncology</i> , 2011, 80, 70-75.	1.9	22
40	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. <i>ESMO Open</i> , 2017, 2, e000261.	4.5	22
41	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 113-120.e1.	2.3	22
42	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.	2.8	22
43	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. <i>Future Oncology</i> , 2022, 18, 2351-2360.	2.4	22
44	One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. <i>Oncologist</i> , 2019, 24, 1593-1600.	3.7	21
45	Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. <i>Acta Oncologica</i> , 2012, 51, 867-872.	1.8	20
46	Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system. <i>Cancer Science</i> , 2020, 111, 3926-3937.	3.9	20
47	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. , 2019, 7, 219.		19
48	S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. <i>ESMO Open</i> , 2017, 2, e000135.	4.5	17
49	Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). <i>Anti-Cancer Drugs</i> , 2011, 22, 576-583.	1.4	16
50	Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. <i>BMC Cancer</i> , 2019, 19, 255.	2.6	16
51	Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11524-11524.	1.6	16
52	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e687-e697.	2.3	15
53	BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000624.	4.5	15
54	Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSCG1003): Detailed analysis of peripheral sensory neuropathy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-701.	1.6	15

#	ARTICLE	IF	CITATIONS
55	Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. <i>Medicine (United States)</i> , 2020, 99, e22250.	1.0	14
56	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 626.	2.6	13
57	Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1016-1022.	1.3	13
58	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	2.3	13
59	Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 614-621.	2.2	13
60	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 217-223.	2.3	13
61	RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapyâ€”Efficacy analysis in Japanese and Western patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4005-4005.	1.6	13
62	Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study. <i>Advances in Therapy</i> , 2022, 39, 296-313.	2.9	13
63	Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 263-263.	1.6	12
64	Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3606-3606.	1.6	12
65	Exploration of potential prognostic biomarkers in aflibercept plus <scp>FOLFIRI</scp> in Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 3565-3572.	3.9	11
66	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instabilityâ€”High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT,) Tj ETQq0 0 0 rgB.7/Overlook 10 Tf 50	3.7	10
67	Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 43-48.	1.3	10
68	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. <i>Clinical Colorectal Cancer</i> , 2018, 17, e719-e732.	2.3	10
69	Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 753-761.	1.3	10
70	Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 721-721.	1.6	10
71	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3530-3530.	1.6	10
72	Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4654-TPS4654.	1.6	10

#	ARTICLE	IF	CITATIONS
73	Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-6.	1.5	9
74	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 687.	2.6	9
75	TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECURSE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 634-634.	1.6	9
76	Onset of neutropenia as an indicator of treatment response in the phase 3 RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 775-775.	1.6	9
77	Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12094-12094.	1.6	9
78	Reverse: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.. <i>Journal of Clinical Oncology</i> , 2018, 36, 557-557.	1.6	9
79	Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 642-642.	1.6	9
80	Characteristics of anal canal cancer in Japan. <i>Cancer Medicine</i> , 2022, 11, 2735-2743.	2.8	9
81	Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769454.	1.8	8
82	Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. <i>Supportive Care in Cancer</i> , 2021, 29, 3277-3285.	2.2	8
83	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
84	Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603. <i>Oncologist</i> , 2022, 27, e642-e649.	3.7	8
85	Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000584.	4.5	7
86	Hypertriglyceridemia induced by S-1: A novel case report and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1020-1025.	0.9	7
87	Phase III RECURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. <i>Journal of Clinical Oncology</i> , 2016, 34, 646-646.	1.6	7
88	APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3523-3523.	1.6	7
89	Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1969-1974.	1.4	7
90	Translational research of VOLTAGE-A: Efficacy predictors of preoperative chemoradiotherapy and consolidation nivolumab in patients with both microsatellite stable and microsatellite instability-high locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 100-100.	1.6	6

#	ARTICLE	IF	CITATIONS
91	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 85-85.	1.6	6
92	A case of immune checkpoint <scp>inhibitor-associated</scp> gastroenteritis detected by ultrasonography. Journal of Clinical Ultrasound, 2021, 49, 605-609.	0.8	6
93	Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancerâ€”HGCSG1401.. Journal of Clinical Oncology, 2017, 35, 778-778.	1.6	6
94	A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of albumin-bilirubin (ALBI) grade.. Journal of Clinical Oncology, 2020, 38, 415-415.	1.6	6
95	Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer, 2017, 17, 837.	2.6	5
96	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology, 2018, 94, 289-296.	1.9	5
97	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatinâ€based or irinotecanâ€based therapy for colorectal cancer. Cancer Science, 2021, 112, 1567-1578.	3.9	5
98	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. European Journal of Cancer, 2021, 154, 296-306.	2.8	5
99	RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapyâ€”An age-group analysis.. Journal of Clinical Oncology, 2015, 33, 11-11.	1.6	5
100	Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3556-3556.	1.6	5
101	Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).. Journal of Clinical Oncology, 2016, 34, 3557-3557.	1.6	5
102	REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecanâ€Biomarker analysis.. Journal of Clinical Oncology, 2018, 36, 3510-3510.	1.6	5
103	A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).. Journal of Clinical Oncology, 2020, 38, TPS3650-TPS3650.	1.6	5
104	A phase II study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1).. Journal of Clinical Oncology, 2013, 31, 70-70.	1.6	5
105	Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Gastric Cancer, 2021, 24, 467-476.	5.3	4
106	Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS).. Journal of Clinical Oncology, 2016, 34, 680-680.	1.6	4
107	Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, 169-169.	1.6	4
108	Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. Global Health & Medicine, 2020, 2, 240-246.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSC0901 and 1002.. Journal of Clinical Oncology, 2014, 32, 663-663.	1.6	4
110	Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2020, 38, 823-823.	1.6	4
111	Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502a€A1. Cancer Science, 2022, 113, 1018-1027.	3.9	4
112	Rapid Screening Using Pathomorphologic Interpretation to Detect <i>BRAF</i> V600E Mutation and Microsatellite Instability in Colorectal Cancer. Clinical Cancer Research, 2022, 28, 2623-2632.	7.0	4
113	A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. Japanese Journal of Clinical Oncology, 2017, 47, 1002-1009.	1.3	3
114	Immune Checkpoint Inhibitor-Induced Colitis Successfully Followed up by Ultrasonography. SN Comprehensive Clinical Medicine, 2020, 2, 215-221.	0.6	3
115	Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen.. Journal of Clinical Oncology, 2021, 39, 106-106.	1.6	3
116	Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study. Biological and Pharmaceutical Bulletin, 2021, 44, 474-477.	1.4	3
117	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. Investigational New Drugs, 2021, 39, 1649-1655.	2.6	3
118	A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSC 1403). Oncologist, 2021, 26, e1675-e1682.	3.7	3
119	Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 2025-2028.	2.2	3
120	A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSC1402).. Journal of Clinical Oncology, 2016, 34, 10127-10127.	1.6	3
121	Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial.. Journal of Clinical Oncology, 2016, 34, 3547-3547.	1.6	3
122	TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.. Journal of Clinical Oncology, 2016, 34, 638-638.	1.6	3
123	PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, TPS776-TPS776.	1.6	3
124	Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) + FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 799-799.	1.6	3
125	VOLTAGE: Multicenter phase 1b/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer.. Journal of Clinical Oncology, 2018, 36, TPS878-TPS878.	1.6	3
126	Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer.. Journal of Clinical Oncology, 2020, 38, 4073-4073.	1.6	3

#	ARTICLE	IF	CITATIONS
127	Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503).. Journal of Clinical Oncology, 2020, 38, 107-107.	1.6	3
128	Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.. Journal of Clinical Oncology, 2020, 38, 5-5.	1.6	3
129	Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression.. Journal of Clinical Oncology, 2020, 38, 538-538.	1.6	3
130	Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.. Journal of Clinical Oncology, 2019, 37, 3528-3528.	1.6	3
131	Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation. Biological and Pharmaceutical Bulletin, 2021, 44, 1819-1823.	1.4	3
132	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS215-TPS215.	1.6	3
133	Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience. Journal of Gastric Cancer, 2016, 16, 177.	2.5	2
134	Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. Journal of Infection and Chemotherapy, 2016, 22, 826-829.	1.7	2
135	Evaluation of Chemotherapy Regimen Management Practice by Oncology-Specialized and Non-specialized Pharmacists Collaboration. Biological and Pharmaceutical Bulletin, 2021, 44, 293-297.	1.4	2
136	Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report. Case Reports in Oncology, 2021, 14, 207-211.	0.7	2
137	Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. International Journal of Clinical Oncology, 2021, 26, 1238-1247.	2.2	2
138	A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer: The SOFT study.. Journal of Clinical Oncology, 2013, 31, 3519-3519.	1.6	2
139	Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3586-3586.	1.6	2
140	Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 4051-4051.	1.6	2
141	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2017, 35, TPS3623-TPS3623.	1.6	2
142	Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.. Journal of Clinical Oncology, 2017, 35, 151-151.	1.6	2
143	Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.. Journal of Clinical Oncology, 2017, 35, 529-529.	1.6	2
144	A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results.. Journal of Clinical Oncology, 2017, 35, 770-770.	1.6	2

#	ARTICLE	IF	CITATIONS
145	TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA.. Journal of Clinical Oncology, 2019, 37, TPS3156-TPS3156.	1.6	2
146	Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 99-99.	1.6	2
147	bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).. Journal of Clinical Oncology, 2019, 37, TPS179-TPS179.	1.6	2
148	A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 707-707.	1.6	2
149	Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.. Journal of Clinical Oncology, 2020, 38, 3516-3516.	1.6	2
150	Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HCGSG 1201). Oncologist, 2022, 27, 340-e374.	3.7	2
151	Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program.. Journal of Clinical Oncology, 2022, 40, 199-199.	1.6	2
152	The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. Cancer Medicine, 2022, , .	2.8	2
153	Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer. Supportive Care in Cancer, 2022, , 1.	2.2	2
154	The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring. Internal Medicine, 2018, 57, 2527-2531.	0.7	1
155	Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open, 2019, 4, e000590.	4.5	1
156	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study. International Journal of Clinical Oncology, 2020, 25, 1800-1806.	2.2	1
157	A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. Cancer Medicine, 2021, 10, 2088-2099.	2.8	1
158	Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, 163-163.	1.6	1
159	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, TPS3625-TPS3625.	1.6	1
160	Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan.. Journal of Clinical Oncology, 2016, 34, 96-96.	1.6	1
161	A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.. Journal of Clinical Oncology, 2017, 35, 722-722.	1.6	1
162	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HCGSG1503): Analysis of tumor location.. Journal of Clinical Oncology, 2018, 36, 802-802.	1.6	1

#	ARTICLE	IF	CITATIONS
163	Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15106-e15106.	1.6	1
164	Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.. Journal of Clinical Oncology, 2019, 37, 624-624.	1.6	1
165	Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.. Journal of Clinical Oncology, 2019, 37, 84-84.	1.6	1
166	A case of hepatic lymphoma showing a mixed pattern on contrast-enhanced ultrasonography. Choonpa Igaku, 2016, 43, 115-122.	0.0	1
167	Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study.. Journal of Clinical Oncology, 2013, 31, 3638-3638.	1.6	1
168	Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902â€”Comparison of administration interval in cetuximab treatment.. Journal of Clinical Oncology, 2015, 33, 746-746.	1.6	1
169	Prospective observational study for the impact of short-term periodic intravenous steroid premedication for gastrointestinal cancer chemotherapy on bone metabolism.. Journal of Clinical Oncology, 2016, 34, 523-523.	1.6	1
170	Clinical implementation of a comprehensive targeted amplicon sequencing system for the patients with gastrointestinal cancer as a real world evidence in Japan.. Journal of Clinical Oncology, 2018, 36, 329-329.	1.6	1
171	Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3560-3560.	1.6	1
172	HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapyâ€”Updated analysis of antitumor efficacy.. Journal of Clinical Oncology, 2020, 38, 108-108.	1.6	1
173	Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. Clinical Drug Investigation, 2021, 41, 53-64.	2.2	1
174	VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.. Journal of Clinical Oncology, 2020, 38, 100-100.	1.6	1
175	Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. BMJ Open, 2022, 12, e048833.	1.9	1
176	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). Oncology, 2020, 98, 719-726.	1.9	0
177	Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naïve patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study.. Journal of Clinical Oncology, 2021, 39, 57-57.	1.6	0
178	Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. Japanese Journal of Clinical Oncology, 2021, 51, 879-885.	1.3	0
179	Discovery of a potential predictive marker for eribulin treatment and novel target genes in BRAF V600E mutant metastatic colorectal cancer using an AI-driven RNA-seq analysis platform: Translational research of the BRAVERY study (EPOC1701).. Journal of Clinical Oncology, 2021, 39, e15532-e15532.	1.6	0
180	Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).. Journal of Clinical Oncology, 2021, 39, TPS4152-TPS4152.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegafur, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer.. Journal of Clinical Oncology, 2012, 30, 141-141.	1.6	0
182	Safety report of a phase II trial of irinotecan plus S-1 (IRIS) with cetuximab in patients with KRAS wild type of metastatic colorectal cancer: HGCSG0902.. Journal of Clinical Oncology, 2012, 30, e14062-e14062.	1.6	0
183	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysisâ€”Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.. Journal of Clinical Oncology, 2012, 30, 3593-3593.	1.6	0
184	Retrospective cohort study on the safety and efficacy of panitumumab (Pmab) for patients with metastatic colorectal cancer (mCRC): The HGCSG1002 studyâ€”Analysis of clinical early predictor for the efficacy.. Journal of Clinical Oncology, 2013, 31, 593-593.	1.6	0
185	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysisâ€”Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.. Journal of Clinical Oncology, 2013, 31, 460-460.	1.6	0
186	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trialâ€”Comparison of the efficacy of KRAS status.. Journal of Clinical Oncology, 2013, 31, 536-536.	1.6	0
187	An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 split cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702â€”Safety analysis.. Journal of Clinical Oncology, 2013, 31, 121-121.	1.6	0
188	Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 studyâ€”Analysis of adverse events.. Journal of Clinical Oncology, 2013, 31, 554-554.	1.6	0
189	Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 studyâ€”Analysis of after cetuximab refractory.. Journal of Clinical Oncology, 2013, 31, 541-541.	1.6	0
190	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies.. Journal of Clinical Oncology, 2013, 31, e14604-e14604.	1.6	0
191	A phase II study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1).. Journal of Clinical Oncology, 2013, 31, 4072-4072.	1.6	0
192	Analysis of Kohn's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.. Journal of Clinical Oncology, 2014, 32, 634-634.	1.6	0
193	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with) Tj ETQq1 1 0iZ84314 rgBT /Over		
194	Comparison of adding cetuximab (Cmab) or panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.. Journal of Clinical Oncology, 2014, 32, 598-598.	1.6	0
195	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies.. Journal of Clinical Oncology, 2014, 32, 603-603.	1.6	0
196	Updated analysis of HERBIS-1: A phase II study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, 98-98.	1.6	0
197	Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: HGCSG0704.. Journal of Clinical Oncology, 2014, 32, 624-624.	1.6	0
198	Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report.. Journal of Clinical Oncology, 2014, 32, 113-113.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGSG1001 (Japanese Skin Toxicity Evaluation Protocol with) Tj ETQq1 1 0.784314 rgBT /Overl	1.6	0
200	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status.. Journal of Clinical Oncology, 2015, 33, 782-782.	1.6	0
201	Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSG0901.. Journal of Clinical Oncology, 2015, 33, 781-781.	1.6	0
202	Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A).. Journal of Clinical Oncology, 2015, 33, 127-127.	1.6	0
203	Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.. Journal of Clinical Oncology, 2015, 33, 743-743.	1.6	0
204	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV.. Journal of Clinical Oncology, 2015, 33, 527-527.	1.6	0
205	ReGISTry Study of High Risk GIST Patients After Complete Resection:The adjuvant therapy and pathological diagnosis in Japan.. Journal of Clinical Oncology, 2015, 33, 10533-10533.	1.6	0
206	Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802)â€”Sub-group analysis by KRAS Exon2 status.. Journal of Clinical Oncology, 2016, 34, 522-522.	1.6	0
207	Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802â€”Analysis of early tumor shrinkage (ETS).. Journal of Clinical Oncology, 2016, 34, 753-753.	1.6	0
208	Phase II trial of bolus 5-FU/I-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502).. Journal of Clinical Oncology, 2016, 34, TPS177-TPS177.	1.6	0
209	Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index.. Journal of Clinical Oncology, 2016, 34, 743-743.	1.6	0
210	Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902â€”Comparison of administration interval in cetuximab treatment.. Journal of Clinical Oncology, 2016, 34, 771-771.	1.6	0
211	Update analysis: Prospective observational study for the impact of short-term periodic steroid premedication for cancer chemotherapy on bone metabolismâ€”ESPRESSO-01 study.. Journal of Clinical Oncology, 2016, 34, e18145-e18145.	1.6	0
212	A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602.. Journal of Clinical Oncology, 2017, 35, TPS809-TPS809.	1.6	0
213	North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003).. Journal of Clinical Oncology, 2017, 35, 807-807.	1.6	0
214	Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.. Journal of Clinical Oncology, 2017, 35, e21688-e21688.	1.6	0
215	Clinical implementation of a comprehensive targeted amplicon sequencing system for cancer in Japan.. Journal of Clinical Oncology, 2017, 35, e13115-e13115.	1.6	0
216	A Case Report of Successful Conversion Therapy with XELOX + Bevacizumab in a Patient with AFP-producing Colon Cancer and Synchronous Liver Metastases. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2018, 43, 845-854.	0.0	0

#	ARTICLE	IF	CITATIONS
217	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.. Journal of Clinical Oncology, 2018, 36, 832-832.	1.6	0
218	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2018, 36, 760-760.	1.6	0
219	Safety of administration of bevacizumab within a week from placement of a totally implantable central venous port system.. Journal of Clinical Oncology, 2018, 36, 589-589.	1.6	0
220	Predictive value of tumor growth rate during previous treatment for tumor response to regorafenib (REGO) and trifluridine/tipiracil (TFTD) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 766-766.	1.6	0
221	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. Journal of Clinical Oncology, 2018, 36, 10094-10094.	1.6	0
222	A retrospective analysis of neoadjuvant chemotherapy followed by surgery or definitive chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 115-115.	1.6	0
223	Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 359-359.	1.6	0
224	HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.. Journal of Clinical Oncology, 2019, 37, TPS183-TPS183.	1.6	0
225	S-1+oxaliplatin with pembrolizumab for advanced gastric cancer: The cohort 1 in a phase IIb KEYNOTE-659 study.. Journal of Clinical Oncology, 2020, 38, 382-382.	1.6	0
226	Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.. Journal of Clinical Oncology, 2020, 38, 4071-4071.	1.6	0
227	HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.. Journal of Clinical Oncology, 2020, 38, TPS4668-TPS4668.	1.6	0
228	The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.. Journal of Clinical Oncology, 2020, 38, 296-296.	1.6	0
229	Quattro-II study: A multicenter randomized phase II study comparing capecitabine plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.. Journal of Clinical Oncology, 2020, 38, TPS267-TPS267.	1.6	0
230	A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain. Anticancer Research, 2022, 42, 343-348.	1.1	0
231	HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy for gastrointestinal cancer.. Journal of Clinical Oncology, 2022, 40, 649-649.	1.6	0
232	A Survey Using a Terminal Care Attitude Scale Intended for Oncologists and Palliative Care Staff. Palliative Care Research, 2022, 17, 51-58.	0.0	0
233	Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 3571-3571.	1.6	0
234	An investigator-initiated phase II trial of a PARP inhibitor niraparib monotherapy for patients with pre-treated, <i>BRCA</i>-mutated, unresectable/recurrent biliary tract, pancreatic, and other gastrointestinal cancers (NIR-B trial).. Journal of Clinical Oncology, 2022, 40, TPS4174-TPS4174.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.. Journal of Clinical Oncology, 2022, 40, 4086-4086.	1.6	0